ASH 2021 | Meta-analysis of cilta-cel in patients with R/R multiple myeloma
Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, is currently being investigated in patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207). Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of findings from a meta-analysis of cilta-cel verus the standard of care. Data from various real world registries and clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134), were analyzed and patients receiving cilta-cel had superior progression-free survival and overall survival. Despite cilta-cel causing more adverse events, patients overall reported a better quality of life. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
